| 55.05 0.775 (1.43%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 66.62 |
1-year : | 77.81 |
| Resists | First : | 57.04 |
Second : | 66.62 |
| Pivot price | 55.25  |
|||
| Supports | First : | 53.96 |
Second : | 52.06 |
| MAs | MA(5) : | 54.82 |
MA(20) : | 55.12 |
| MA(100) : | 49.09 |
MA(250) : | 50.24 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 39.1 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 63.33 | Low : | 42.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMY ] has closed above bottom band by 43.7%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 55.13 - 55.44 | 55.44 - 55.72 |
| Low: | 53.5 - 53.91 | 53.91 - 54.29 |
| Close: | 54.46 - 55.05 | 55.05 - 55.59 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Fri, 30 Jan 2026
Citi Raises Bristol-Myers (BMY) Target as Sector Outlook Improves into 2026 - Insider Monkey
Fri, 30 Jan 2026
Bristol-Myers Squibb Company (NYSE:BMY) Is Largely Controlled by Institutional Shareholders Who Own 80% of the Company - 富途牛牛
Fri, 30 Jan 2026
New York State Common Retirement Fund Has $106.84 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fri, 30 Jan 2026
A Look At Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum - simplywall.st
Thu, 29 Jan 2026
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Finviz
Thu, 29 Jan 2026
Bristol Myers Squibb Company $BMY Stock Position Increased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 2,030 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 82 (%) |
| Shares Short | 36,580 (K) |
| Shares Short P.Month | 33,890 (K) |
| EPS | 2.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.1 |
| Profit Margin | 12.5 % |
| Operating Margin | 31.5 % |
| Return on Assets (ttm) | 9.3 % |
| Return on Equity (ttm) | 33.7 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 17.22 |
| Sales Per Share | 23.54 |
| EBITDA (p.s.) | 9.42 |
| Qtrly Earnings Growth | 80.9 % |
| Operating Cash Flow | 16,620 (M) |
| Levered Free Cash Flow | 14,720 (M) |
| PE Ratio | 18.53 |
| PEG Ratio | 0 |
| Price to Book value | 6.04 |
| Price to Sales | 2.33 |
| Price to Cash Flow | 6.75 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 1.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |